The High “Cost” of Experimental Drugs Obtained Through Health Litigation in Brazil

BACKGROUND: Brazilian patients have legal right to access unlicensed medicines undergoing clinical research, if there is evidence of efficacy and safety. This study investigated the occurrence of serious adverse events related to very high-cost medicines from clinical studies, expanded access and co...

Descripción completa

Detalles Bibliográficos
Autores principales: da Silva, Ricardo Eccard, Lima, Elisangela da Costa, Novaes, Maria Rita C. G., Osorio-de-Castro, Claudia G. S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7248274/
https://www.ncbi.nlm.nih.gov/pubmed/32508660
http://dx.doi.org/10.3389/fphar.2020.00752

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7248274/
https://www.ncbi.nlm.nih.gov/pubmed/32508660
http://dx.doi.org/10.3389/fphar.2020.00752

Ejemplares similares